Detalhe da pesquisa
1.
Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer.
Cell
; 155(3): 552-66, 2013 Oct 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-24243015
2.
Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer.
Genes Dev
; 30(11): 1289-99, 2016 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27298335
3.
Development of Human Adrenocortical Adenoma (HAA1) Cell Line from Zona Reticularis.
Int J Mol Sci
; 24(1)2022 Dec 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-36614027
4.
Genome-wide copy number variation pattern analysis and a classification signature for non-small cell lung cancer.
Genes Chromosomes Cancer
; 56(7): 559-569, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28379620
5.
ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers.
Proc Natl Acad Sci U S A
; 111(41): 14788-93, 2014 Oct 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-25267614
6.
Microtubule affinity-regulating kinase 2 is associated with DNA damage response and cisplatin resistance in non-small cell lung cancer.
Int J Cancer
; 137(9): 2072-82, 2015 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25907283
7.
Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression.
Genome Res
; 22(7): 1197-211, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22613842
8.
Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events.
Genome Res
; 22(12): 2315-27, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23033341
9.
Proteomic signatures associated with p53 mutational status in lung adenocarcinoma.
Proteomics
; 14(23-24): 2750-9, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25331784
10.
Analysis of TP53 mutation status in human cancer cell lines: a reassessment.
Hum Mutat
; 35(6): 756-65, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24700732
11.
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.
Cancer Cell
; 10(1): 25-38, 2006 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-16843263
12.
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer.
Cancer Cell
; 10(1): 39-50, 2006 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-16843264
13.
Genomic alterations in cultured human embryonic stem cells.
Nat Genet
; 37(10): 1099-103, 2005 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-16142235
14.
Characterizing the cancer genome in lung adenocarcinoma.
Nature
; 450(7171): 893-8, 2007 Dec 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-17982442
15.
Gallbladder cancer: lessons from a rare tumour.
Nat Rev Cancer
; 4(9): 695-706, 2004 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-15343276
16.
SV40 and human tumours: myth, association or causality?
Nat Rev Cancer
; 2(12): 957-64, 2002 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-12459734
17.
Malignant mesothelioma: facts, myths, and hypotheses.
J Cell Physiol
; 227(1): 44-58, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21412769
18.
Mitochondrial DNA mutations in respiratory complex-I in never-smoker lung cancer patients contribute to lung cancer progression and associated with EGFR gene mutation.
J Cell Physiol
; 227(6): 2451-60, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21830212
19.
Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer.
Int J Cancer
; 130(8): 1733-44, 2012 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21544811
20.
The circadian clock gene BMAL1 is a novel therapeutic target for malignant pleural mesothelioma.
Int J Cancer
; 131(12): 2820-31, 2012 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22510946